|
1
|
Hong W and Dong E: The past, present and
future of breast cancer research in China. Cancer Lett. 351:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Turati F, Carioli G, Bravi F, Ferraroni M,
Serraino D, Montella M, Giacosa A, Toffolutti F, Negri E, Levi F
and La Vecchia C: Mediterranean diet and breast cancer risk.
Nutrients. 10:E3262018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ni W, Chen B, Zhou G, Lu C, Xiao M, Guan
C, Zhang Y, He S, Shen A and Ni R: Overexpressed nuclear BAG-1 in
human hepatocellular carcinoma is associated with poor prognosis
and resistance to doxorubicin. J Cell Biochem. 114:2120–2130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pelden S, Insawang T, Thuwajit C and
Thuwajit P: The trefoil factor 1 (TFF1) protein involved in
doxorubicininduced apoptosis resistance is upregulated by estrogen
in breast cancer cells. Oncol Rep. 30:1518–1526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunha NL, Teixeira GM, Martins TD, Souza
AR, Oliveira PF, Simaro GV, Rezende KC, Gonçalves Ndos S, Souza DG,
Tavares DC, et al: (−)-Hinokinin induces G2/M arrest and
contributes to the antiproliferative effects of doxorubicin in
breast cancer cells. Planta Medica. 82:530–538. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hermawan A, Wagner E and Roidl A:
Consecutive salinomycin treatment reduces doxorubicin resistance of
breast tumor cells by diminishing drug efflux pump expression and
activity. Oncol Rep. 35:1732–1740. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wijdeven RH, Pang B, Assaraf YG and
Neefjes J: Old drugs, novel ways out: Drug resistance toward
cytotoxic chemotherapeutics. Drug Resist Updat. 28:65–81. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Das CK, Linder B, Bonn F, Rothweiler F,
Dikic I, Michaelis M, Cinatl J, Mandal M and Kögel D: BAG3
overexpression and cytoprotective autophagy mediate apoptosis
resistance in chemoresistant breast cancer cells. Neoplasia.
20:263–279. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang X, Wan G, Mlotshwa S, Vance V,
Berger FG, Chen H and Lu X: Oncogenic Wip1 phosphatase is inhibited
by miR-16 in the DNA damage signaling pathway. Cancer Res.
70:7176–7186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM
and Zhang GZ: Biological functions of microRNAs: A review. J
Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cai Y, Yu X, Hu S and Yu J: A brief review
on the mechanisms of miRNA regulation. Genomics Proteomics
Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wahid F, Shehzad A, Khan T and Kim YY:
MicroRNAs: Synthesis, mechanism, function, and recent clinical
trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Calin GA, Cimmino A, Fabbri M, Ferracin M,
Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI,
et al: MiR-15a and miR-16-1 cluster functions in human leukemia.
Proc Natl Acad Sci USA. 105:5166–5171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rivas MA, Venturutti L, Huang YW,
Schillaci R, Huang TH and Elizalde PV: Downregulation of the
tumor-suppressor miR-16 via progestin-mediated oncogenic signaling
contributes to breast cancer development. Breast Cancer Res.
14:R772012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mobarra N, Shafiee A, Rad SM, Tasharrofi
N, Soufi-Zomorod M, Hafizi M, Movahed M, Kouhkan F and Soleimani M:
Overexpression of microRNA-16 declines cellular growth,
proliferation and induces apoptosis in human breast cancer cells.
In vitro Cell Dev Biol Anim. 51:604–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pekarsky Y, Balatti V and Croce CM: BCL2
and miR-15/16: From gene discovery to treatment. Cell Death Differ.
25:21–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Booser DJ, Esteva FJ, Rivera E, Valero V,
Esparza-Guerra L, Priebe W and Hortobagyi GN: Phase II study of
liposomal annamycin in the treatment of doxorubicin-resistant
breast cancer. Cancer Chemother Pharmacol. 50:6–8. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American joint
committee on cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Côme C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shah MV, Wiktor AE, Meyer RG, Tenner KS,
Ballman KV, Green SJ, Sukov WR, Ketterling RP, Perez EA and Jenkins
RB: Change in pattern of HER2 fluorescent in situ hybridization
(FISH) results in breast cancers submitted for FISH testing:
Experience of a reference laboratory using US food and drug
administration criteria and American society of clinical oncology
and college of American pathologists guidelines. J Clin Oncol.
34:3502–3510. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei T, Ye P, Peng X, Wu LL and Yu GY:
Prognostic value of miR-222 in various cancers: A systematic review
and meta-analysis. Clin Lab. 62:1387–1395. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gonen N and Assaraf YG: Antifolates in
cancer therapy: Structure, activity and mechanisms of drug
resistance. Drug Resist Updat. 15:183–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Borst P, Jonkers J and Rottenberg S: What
makes tumors multidrug resistant? Cell Cycle. 6:2782–2787. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo L, Zhao Y, Yang S, Cai M, Wu Q and
Chen F: Genome-wide screen for aberrantly expressed miRNAs reveals
miRNA profile signature in breast cancer. Mol Biol Rep.
40:2175–2186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harquail J, Benzina S and Robichaud GA:
MicroRNAs and breast cancer malignancy: An overview of
miRNA-regulated cancer processes leading to metastasis. Cancer
Biomark. 11:269–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhan XH, Xu QY, Tian R, Yan H, Zhang M, Wu
J, Wang W and He J: MicroRNA16 regulates glioma cell proliferation,
apoptosis and invasion by targeting Wip1-ATM-p53 feedback loop.
Oncotarget. 8:54788–54798. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liang X, Xu K, Xu Y, Liu J and Qian X:
B1-induced caspase-independent apoptosis in MCF-7 cells is mediated
by down-regulation of Bcl-2 via p53 binding to P2 promoter TATA
box. Toxicol Appl Pharmacol. 256:52–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Srivastava RK, Sasaki CY, Hardwick JM and
Longo DL: Bcl-2-mediated drug resistance: Inhibition of apoptosis
by blocking nuclear factor of activated T lymphocytes
(NFAT)-induced Fas ligand transcription. J Exp Med. 190:253–265.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang T, Xu F, Sheng Y, Zhang W and Chen Y:
A targeted proteomics approach to the quantitative analysis of
ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in
breast cancer. Anal Bioanal Chem. 408:7491–7503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marcel V, Catez F and Diaz JJ: p53, a
translational regulator: Contribution to its tumour-suppressor
activity. Oncogene. 34:5513–5523. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto M, Hosoda M, Nakano K, Jia S,
Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y and Yamashita H: p53
accumulation is a strong predictor of recurrence in estrogen
receptor-positive breast cancer patients treated with aromatase
inhibitors. Cancer Sci. 105:81–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Varna M, Bousquet G, Plassa LF, Bertheau P
and Janin A: TP53 status and response to treatment in breast
cancers. J Biomed Biotechnol. 2011:2845842011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Casey G, Lo-Hsueh M, Lopez ME, Vogelstein
B and Stanbridge EJ: Growth suppression of human breast cancer
cells by the introduction of a wild-type p53 gene. Oncogene.
6:1791–1797. 1991.PubMed/NCBI
|
|
39
|
Fabbri M, Bottoni A, Shimizu M, Spizzo R,
Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE,
et al: Association of a microRNA/TP53 feedback circuitry with
pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
JAMA. 305:59–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cai CK, Zhao GY, Tian LY, Liu L, Yan K, Ma
YL, Ji ZW, Li XX, Han K, Gao J, et al: miR-15a and miR-16-1
downregulate CCND1 and induce apoptosis and cell cycle arrest in
osteosarcoma. Oncol Rep. 28:1764–1770. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang QQ, Liu B and Yuan T: MicroRNA-16
inhibits bladder cancer proliferation by targeting cyclin D1. Asian
Pac J Cancer Prev. 14:4127–4130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Patel N, Garikapati KR, Pandita RK, Singh
DK, Pandita TK, Bhadra U and Bhadra MP: Erratum: MiR-15a/miR-16
down-regulates BMI1, impacting Ub-H2A mediated DNA repair and
breast cancer cell sensitivity to doxorubicin. Sci Rep.
7:129322017. View Article : Google Scholar : PubMed/NCBI
|
